| Abstract | BACKGROUND: Cabergoline (CAB) has been proposed as the first-line treatment in the management of prolactin (PRL)-secreting tumors (prolactinoma [PRLoma]), including those resistant to standard dopamine agonist (DAA) therapy. The authors report remarkable effects of CAB in a case of huge PRLoma that had been resistant to a long-term, high-dose treatment with bromocriptine (BRC). CASE DESCRIPTION: A 28-year-old man was originally presented with oculomotor paresis when he was 9 years old. After 2 partial resections, he was treated with a maximum 60-mg/d dose of BRC for 18 years. Nonetheless, the tumor grew up to more than 8 cm in diameter, serum PRL increased over 60000 ng/mL, and his visual acuity deteriorated. Cabergoline normalized serum PRL level, shrank the tumor mass remarkably, and caused marked improvement of visual acuity. CONCLUSION: Prolactin normalization and significant tumor shrinkage could be achieved with CAB even in extremely BRC-resistant PRLomas. Surgical resection should be reserved only for patients who are resistant to cabergoline or who require urgent decompression in such emergency as massive intratumoral hemorrhage. |
| Authors | Yasuhiro Kawabata, Yasushi Ueno, Fumihiko Horikawa, Hidenori Miyake, Nobuhiro Miki, Masami Ono
(Affiliation: Department of Neurosurgery, Hamamatsu Rosai Hospital, Shizuoka 430-8525, Japan. ykawabata-kyt at umin.ac.jp)
|
| Journal | Surgical neurology
(Surg Neurol)
Vol. 69
Issue 1
Pg. 85-8; discussion 88
(Jan 2008)
ISSN: 0090-3019 United States |
| PMID | 17967478
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antineoplastic Agents
- Dopamine Agonists
- Ergolines
- Bromocriptine
- cabergoline
|
| Topics |
- Adult
- Antineoplastic Agents
(therapeutic use)
- Bromocriptine
(therapeutic use)
- Dopamine Agonists
(therapeutic use)
- Drug Resistance, Neoplasm
- Ergolines
(therapeutic use)
- Humans
- Male
- Pituitary Neoplasms
(drug therapy, pathology)
- Prolactinoma
(drug therapy, pathology)
- Treatment Outcome
|
